Designing siRNA for Silencing Polo-Like Kinase 1 (Plk1) Gene of Prostate Cancer
Main Article Content
Abstract
Prostate cancer is the most commonly occurring cancer in American men, next to skin cancer. Existing treatment options and surgical intervention are unable to manage this cancer effectively. Therefore, continuing efforts are ongoing to establish novel mechanism-based targets and strategies for its management. PLK1 plays a key role in the mitotic entry of proliferating cells and regulates many aspects of mitosis necessary for successful cytokinesis. PLK1 is overexpressed in many tumor types, with aberrant elevation frequently constituting a prognostic indicator of poor disease outcome. Our study indicates that PLK1 could be an excellent target for the treatment as well as chemoprevention of prostate cancer.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
IJCERT Policy:
The published work presented in this paper is licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This means that the content of this paper can be shared, copied, and redistributed in any medium or format, as long as the original author is properly attributed. Additionally, any derivative works based on this paper must also be licensed under the same terms. This licensing agreement allows for broad dissemination and use of the work while maintaining the author's rights and recognition.
By submitting this paper to IJCERT, the author(s) agree to these licensing terms and confirm that the work is original and does not infringe on any third-party copyright or intellectual property rights.
References
Landis, S. H., Murray, T., Bolden, S., & Wing, P. A. (1998). Cancer statistics, 1998. CA. Cancer J. Clin., 48, 6-29.
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., ... Thun, M. J. (2004). Cancer statistics. CA. Cancer J. Clin., 54, 8-29.
Reagan-Shaw, S., & Ahmad, N. (2005). Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J., 19, 611-613.
Talcott, J. A., Rieker, P., Clark, J. A., Propert, K. J., Weeks, J. C., Beard, C. J., ... Kantoff, P. W. (1998). Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study. J. Clin. Oncol., 16, 275-283.
Quinn, M., & Babb, P. (2002). Patterns and trends in prostate cancer incidence, survival, prevalence, and mortality. Part I: International comparisons. BJU Int., 90, 162-164.
Herbert, J. R., Ghumare, S. S., & Gupta, P. C. (2006). Stage at diagnosis and relative differences in breast and prostate cancer incidence in India: Comparison with the United States. Asian. Pac. J. Cancer. Prev., 7, 547-555.
Daskivich, T. J., & Oh, W. K. (2006). Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: Insight into mechanisms? Urology, 67, 15-17.
Gallagher, E., & Gapstur, R. (2006). Hormone-refractory prostate cancer: A shifting paradigm in treatment. Clin. J. Oncol. Nurs., 10, 233-240.
Golsteyn, R. M., Schultz, S. J., Bartek, J., Ziemiecki, A., Ried, T., & Nigg, E. A. (1994). Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J. Cell Sci., 107, 1509-1517.
Glover, D. M., Hagan, I. M., & Tavares, A. A. (1998). Polo-like kinases: A team that plays throughout mitosis. Genes Dev., 12, 3777-3787.
Donaldson, M. M., Tavares, A. A., Ohkura, H., Deak, P., & Glover, D. M. (2001). Metaphase arrest with centromere separation in polo mutants of Drosophila. J. Cell Biol., 153, 663-676.
Lane, H. A., & Nigg, E. A. (1996). Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell Biol., 135(6 Pt 2), 1701-1713.
Alexandru, G., Uhlmann, F., Mechtler, K., Poupart, M. A., & Nasmyth, K. (2001). Phosphorylation of the cohesin subunit Scc1 by Polo/Cdc5 kinase regulates sister chromatid separation in yeast. Cell., 105, 459-472.
Sumara, I., Vorlaufer, E., Stukenberg, P. T., Kelm, O., Redemann, N., Nigg, E. A., & Peters, J. M. (2002). The dissociation of cohesin from chromosomes in prophase is regulated by polo-like kinase. Mol. Cell, 9, 515-525.
Lansing, T. J., McConnell, R. T., Duckett, D. R., Spehar, G. M., Knick, V. B., Hassler, D. F., ... Gilmer, T. M. (2007). In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol. Cancer Ther., 6, 450-459.
van Vugt, M. A., Bras, A., & Medema, R. H. (2004). Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol. Cell, 15, 799-811.
van Vugt, M. A., van de Weerdt, B. C., Vader, G., Janssen, H., Calafat, J., Klompmaker, R., ... Medema, R. H. (2004). Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J. Biol. Chem., 279, 36841-36854.
McInnes, C., Mezna, M., & Fischer, P. M. (2005). Progress in the discovery of polo-like kinase inhibitors. Curr. Top. Med. Chem., 5, 181-197.
McInnes, C., Mazumdar, A., Mezna, M., Meades, C., Midgley, C., Scaerou, F., ... Walkinshaw, M. (2006). Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat. Chem. Biol., 2(11), 608-617.
Seong, Y. S., Kamijo, K., Lee, J. S., Fernandez, E., Kuriyama, R., Miki, T., & Lee, K. S. (2002). A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J. Biol. Chem., 277(35), 32282-32293.
Leung, G. C., Hudson, J. W., Kozarova, A., Davidson, A., Dennis, J. W., & Sicheri, F. (2002). The Sak polo-box comprises a structural domain sufficient for mitotic subcellular localization. Nat. Struct. Biol., 9, 719-724.
Golsteyn, R. M., Mundt, K. E., Fry, A. M., & Nigg, E. A. (1995). Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J. Cell Biol., 129(6), 1617-1628.
Hamanaka, R., Smith, M. R., O'Connor, P. M., Maloid, S., Mihalic, K., Spivak, J. L., ... Ferris, D. K. (1995). Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J. Biol. Chem., 270(36), 21086-21091.
Hamanaka, R., Maloid, S., Smith, M. R., O'Connell, C. D., Longo, D. L., & Ferris, D. K. (1994). Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell. Growth. Differ., 5(3), 249-257.
Holtrich, U., Wolf, G., Brauninger, A., Karn, T., Bohme, B., Rubsamen-Waigmann, H., & Strebhardt, K. (1994). Induction and downregulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc. Natl. Acad. Sci. USA., 91, 1736-1740.
Smith, M. R., Wilson, M. L., & Hamanaka, R. (1997). Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem. Biophys. Res. Commun., 234, 397-405.
Zhang, C., Pei, J., Kumar, D., Sakabe, I., Boudreau, H. E., Gokhale, P. C., & Kasid, U. N. (2007). Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Methods. Mol. Biol., 361, 163-185.
Spänkuch, B., Steinhauser, I., Wartlick, H., Kurunci-Csacsko, E., Strebhardt, K. I., & Langer, K. (2008). Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia, 10(3), 223-234.
Sui, G., Soohoo, C., Affar, B., Gay, F., Shi, Y., & Forrester, W. C. (2002). A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA., 99, 5515-5520.